Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Moving on

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on May 13, 2021 3:17pm

111 Views

Post# 33196425

RE:RE:Moving on

Thank you for the insights. Most of all, I hope the treatment works. Any thoughts of trialing the TH1902 if it shows decent results?

juniper88 wrote: The difference between TH1902 and TH1904 is the payload, nothing else. Yes, Thera initially used TH1904 (doxorubicin payload) to for the preclinical ovarian cancer work. But then they used TH1902 (docetaxol payload) and found it actually worked better on ovarian cancer. than TH1904.

Sortilin receptor seems to be higher expressed as the disease gets to a later stage and the higher the grade is. There are 4 major subtypes in ovarian cancer but most (70%) are High Grade Serous ovarian cancer, which is the most malignant. And most are diagnosed at a later stage (III or IV). The hope in the study below was that if the cancer was diagnosed in an earlier stage then more women could be cured or survive longer.

From the approximately 20,000 women diagnosed with Ovarian cancer in the United States each year more than 70% will die within 5 years and 95% within 10 years. I believe if TH1902 works then these women are the candidates for TH1902. These would be the women most likely to have overexpressed sortilin receptor.

We are very early still. One of my questions is would it be possible to use TH1902 as a maintance treatment? To keep the cancer under control indefinetely?

As for possible cost. My wife had another re-occurence in December 2020. The oncologists didn't think that platinum based chemo would help much but to everyone's surprise she has responded well. So, the oncologist has recommended a parp inhibitor maintenance which could increase PFS by a few months. The cost of this treatment is about $11,000 per month (not covered by OHIP). If TH1902 can keep cancer patients (not just ovarian cancer) alive and be used as a maintenance treatment how much would that add up to?

scarlet1967 wrote:
Ovarian cancer: Setback as major screening trial fails to save lives

Ovarian cancer: Setback as major screening trial fails to save lives

TH1904 seems to be targeting ovarian cancer as per google,:

“The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.”